

Attorney Docket No. TLIK-043/02US


Serial No. 10/716,652

Page 2

Claim amendments:

1. - 43. (cancelled)

44. (new) A compound of the formula:



where:

each of W, X and Y is independently CR⁶R⁷, N-R⁷, O, or S, provided that at least one of W, X, and Y contains a non-carbon ring atom, and at least one of W, X, and Y contains a carbon ring atom;

Z is N or C-R⁸;

each of R¹, R², R⁶, and R⁸ is independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR⁹, -SR⁹, -NR⁹R¹⁰, -NR⁹(carboxy(lower alkyl)), -C(=O)R⁹, -C(=O)OR⁹, -C(=O)NR⁹R¹⁰, -OC(=O)R⁹, -SO₂R⁹, -OSO₂R⁹, -SO₂NR⁹R¹⁰, -NR⁹SO₂R¹⁰, or -NR⁹C(=O)R¹⁰, where R⁹ and R¹⁰ are independently hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₁₋₂ alkyl)₂, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or heteroaryl(lower alkyl), or R⁹ and R¹⁰ together are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁₋₂ alkyl) group;

R³ and R⁴ are independently hydrogen or lower alkyl or together are -(CH₂)₄₋₆;

each R⁷ is independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl),

688238 v1/PA
#11q011.DOC

Attorney Docket No. TLIK-043/02US

Serial No. 10/716,652

Page 3

$-\text{C}(=\text{O})\text{R}^9$, $-\text{C}(=\text{O})\text{OR}^9$, $-\text{C}(=\text{O})\text{NR}^9\text{R}^{10}$, $-\text{SO}_2\text{R}^9$, or $-\text{SO}_2\text{NR}^9\text{R}^{10}$, where R^9 and R^{10} are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $\text{N}(\text{C}_{1-2}\text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(\text{CH}_2)_{4-6}$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)), or N-(optionally substituted C_{1-2} alkyl) group;

R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-\text{CF}_3$, halo(lower alkyl), halogen, nitro, $-\text{CN}$, $-\text{OR}^{15}$, $-\text{SR}^{15}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{15}$, $-\text{C}(=\text{O})\text{OR}^{15}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{OC}(=\text{O})\text{R}^{15}$, $-\text{SO}_2\text{R}^{15}$, $-\text{SO}_2\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{15}\text{SO}_2\text{R}^{16}$, or $-\text{NR}^{15}\text{C}(=\text{O})\text{R}^{16}$, where R^{15} and R^{16} are independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, $-\text{CF}_3$, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaryl(lower alkyl), or together are $-(\text{CH}_2)_{4-6}$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group; each R^{14} is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-\text{CF}_3$, $-\text{OR}^{17}$, $-\text{NR}^{17}\text{R}^{18}$, $-\text{C}(=\text{O})\text{R}^{17}$, $-\text{C}(=\text{O})\text{OR}^{17}$, $-\text{O}(\text{CH}_2)_m\text{C}(=\text{O})\text{OR}^{17}$, where m is an integer of 1 to 4, or $-\text{C}(=\text{O})\text{NR}^{17}\text{R}^{18}$, where R^{17} and R^{18} are independently, hydrogen, lower alkyl, alkenyl, alkynyl, $-\text{CF}_3$, optionally substituted heterocycloalkyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl) or, together, are $-(\text{CH}_2)_{4-6}$, optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group; and

n is an integer of 0 to 4;

or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

Attorney Docket No. TLIK-043/02US

Serial No. 10/716,652

Page 4

45. (new) The compound of claim 44, where W and Y are O, X is CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

46. (new) The compound of claim 44, where W and X are each CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, Y is O, and Z is C-H.

47. (new) The compound of claim 44, where W is O, X and Y are each CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

48. (new) The compound of claim 44, where W and X are each CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is N.

49. (new) The compound of claim 44, where W is CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, X is O, and Z is N.

50. (new) The compound of claim 44, where W is O, X is CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is N.

51. (new) The compound of claim 44, where R^1 is hydrogen, optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9$ [carboxy(lower alkyl)], $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

Attorney Docket No. TLIK-043/02US
Serial No. 10/716,652
Page 5

52. (new) The compound of claim 44, where R^2 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$,

$-C(=O)OR^9$, or $-C(=O)NR^9R^{10}$, where R^9 and R^{10} are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ - optionally interrupted by one O, S, NH, N-(aryl), N-[aryl(lower alkyl)], N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

53. (new) The compound of claim 44 where R^3 and R^4 are independently hydrogen or lower alkyl.

54. (new) The compound of claim 44, where R^6 and R^7 are independently hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), $-C(=O)R^9$,

$-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2R^9$, or $-SO_2NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

55. (new) The compound of claim 44, where R^8 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, $-OR^9$,

$-NR^9R^{10}$, $-C(=O)R^9$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-OC(=O)R^9$, $-SO_2R^9$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{10}$ or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ - optionally interrupted by

Attorney Docket No. TLIK-043/02US

Serial No. 10/716,652

Page 6

one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁₋₂ alkyl) group.

56. (new) The compound of claim 44, where R¹ and R² are independently hydrogen, lower alkyl, halogen, optionally lower alkyl substituted heterocycloalkyl, -OR⁹, -SR⁹, or -NR⁹R¹⁰, where R⁹ and R¹⁰ are hydrogen, lower alkyl or optionally substituted aryl.

57. (new) The compound of claim 44, where R¹, R², and R⁸ are independently optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, -OR⁹, -NR⁹[carboxy(lower alkyl)], -C(=O)OR⁹, -C(=O)NR⁹R¹⁰, -SO₂NR⁹R¹⁰, or -NR⁹C(=O)R¹⁰, where R⁹ and R¹⁰ are independently, hydrogen, lower alkyl, or R⁹ and R¹⁰ together are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁₋₂ alkyl) group.

58. (new) The compound of claim 44, where R¹, R³, and R⁴ are hydrogen.

59. (new) The compound of claim 44, where R¹³ is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR¹⁵, -SR¹⁵, -NR¹⁵R¹⁶, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)NR¹⁵R¹⁶, or -NR¹⁵C(=O)R¹⁶, where R¹⁵ and R¹⁶ are independently hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, or halo(lower alkyl).

60. (new) The compound of claim 44, where R¹³ is alkynyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -CF₃, -CN, -OR¹⁵, -C(=O)R¹⁵, -C(=O)OR¹⁵, or -C(=O)NR¹⁵R¹⁶, where R¹⁵ and R¹⁶ are independently, hydrogen, lower alkyl, halo(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl) or R¹⁵ and R¹⁶ together are -(CH₂)₄₋₆-, optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.

Attorney Docket No. TLIK-043/02US

Serial No. 10/716,652

Page 7

61. (new) The compound of claim 44, where each R^{14} is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-CF_3$, $-OR^{17}$, $-NR^{17}R^{18}$, $-C(=O)R^{17}$, $-C(=O)OR^{17}$, $-O(CH_2)_mC(=O)OR^{17}$, where m is an integer of 1 to 4, or $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.

62. (new) The compound of claim 44, where each R^{14} is independently halogen, $-CF_3$, $-OR^{17}$, $-C(=O)OR^{17}$, $-O(CH_2)_mC(=O)OR^{17}$, where m is an integer of 1 to 4, or $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are independently, hydrogen, lower alkyl, optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl), or R^{17} and R^{18} together are $-(CH_2)_{4-6}-$, optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

63. (new) The compound of claim 44 where R^{13} is not hydrogen and n is 1 or 2.

64. (new) The compound of claim 63 where n is 1.

65. (new) The compound of claim 44 that is selected from:

2H-benzo[d]1,3-dioxolan-5-yl-N-([(3-chloro-4-hydroxyphenyl)amino]carbonyl)-carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([(3,4-dichlorophenyl)amino]carbonyl)carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([(2,6-bis(methylethyl)phenyl)amino]carbonyl)-carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([(4-hydroxyphenyl)amino]carbonyl)carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([(3-chloro-4-methoxyphenyl)amino]carbonyl)-carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([(3-chlorophenyl)amino]carbonyl)carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[(phenylamino)carbonyl]carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(5-chloro-2-hydroxyphenyl)amino]carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-fluorophenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(2,6-difluorophenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(2,3-difluorophenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(4-fluorophenyl)amino]carbonyl)carboxamide;

688238 v1/PA
#1q011.DOC

Attorney Docket No. TLIK-043/02US

Serial No. 10/716,652

Page 8

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(4-chlorophenyl)amino}carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3,4-difluorophenyl)amino}carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[4-(trifluoromethyl)phenyl]amino}carbonyl}-
carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[3-(trifluoromethyl)phenyl]amino}carbonyl}-
carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(4-nitrophenyl)amino}carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[4-nitro-3-(trifluoromethyl)phenyl]amino}-
carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[4-chloro-3-(trifluoromethyl)phenyl]amino}-
carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(4-bromophenyl)amino}carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3-bromophenyl)amino}carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{(3-cyanophenyl)amino}carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{(2,4-dichlorophenyl)amino}carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{(4-methoxyphenyl)amino}carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{(4-iodophenyl)amino}carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{(3-iodophenyl)amino}carbonyl}carboxamide;
4-{{[(2H-benzo[d]1,3-dioxolan-5-ylcarbonylamino)carbonyl]amino}benzamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{[3-fluoro-4-(trifluoromethyl)phenyl]amino}carbonyl}-
carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl}-
carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[4-phenylphenyl]amino}carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[3-(trifluoromethoxy)phenyl]amino}carbonyl}-
carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[3-(trifluoromethylthio)phenyl]amino}carbonyl}-
carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl}-
carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[3-(methylethyl)phenyl]amino}carbonyl}-

Attorney Docket No. TLIK-043/02US

Serial No. 10/716,652

Page 9

carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-ethylphenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-ethoxyphenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(methylethoxy)phenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(tert-butyl)phenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-phenylphenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-chloro-4-methylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-iodo-4-methylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(4-methyl-3-(trifluoromethyl)phenyl)amino]-
carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-phenoxyphenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-nitrophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3,5-dichlorophenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-acetylphenyl)amino]carbonyl}carboxamide;

methyl 3-{[(2H-benzo[3,4-d]1,3-dioxolen-5-ylcarbonylamino)carbonyl]amino}benzoate;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(1H-1,2,3,4-tetraazol-5-yl)phenyl)amino]-
carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-ethynylphenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-chloro-2-methylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(5-chloro-2-methylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-chloro-2,6-diethylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(5-iodo-2-methylphenyl)amino]carbonyl}-
carboxamide;

Attorney Docket No. TLIK-043/02US

Serial No. 10/716,652

Page 10

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3-(2-pyridyl)phenyl)amino}carbonyl}-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3-(1,3-thiazol-2-yl)phenyl)amino}carbonyl}-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3-(3-thienyl)phenyl)amino}carbonyl}-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3-(2-furyl)phenyl)amino}carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3-(2-thienyl)phenyl)amino}carbonyl}-carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-{{(3-icyanophenyl)amino}carbonyl}-carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-{{(3-iodophenyl)amino}carbonyl}-carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-({[3-(trifluoromethyl)phenyl]amino}-carbonyl)carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-({[3-(methylethoxy)phenyl]amino}-carbonyl)carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl) carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{(3-chlorophenyl)methylamino}carbonyl}-N-methylcarboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{{(3-chlorophenyl)amino}carbonyl}-N-methylcarboxamide;

N-{{(3,4-dichlorophenyl)amino}carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;

N-{{(3-chlorophenyl)amino}carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;

2,3-dihydrobenzo[b]furan-5-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;

2,3-dihydrobenzo[b]furan-5-yl-N-{{(4-fluorophenyl)amino}carbonyl}carboxamide; and

2,3-dihydrobenzo[b]furan-5-yl-N-{{(4-methoxyphenyl)amino}carbonyl}carboxamide;

and the pharmaceutically acceptable salts thereof, as single stereoisomers or mixtures of stereoisomers.

Attorney Docket No. TLIK-043/02US
Serial No. 10/716,652
Page 11

66. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 44 and a pharmaceutically acceptable excipient.
67. (new) The pharmaceutical composition of claim 66, further comprising an anti-inflammatory drug, cytokine, or immunomodulator.
68. (new) A method of treating an allergic, inflammatory, or autoimmune disorder or disease, comprising administering a therapeutically effective amount of a compound of claim 44 to a mammal in need of such treatment.
69. (new) The method of claim 68 where the compound is administered in combination with an anti-inflammatory drug, cytokine, or immunomodulator.
70. (new) The method of claim 68 where the allergic, inflammatory, or autoimmune disorder or disease is selected from the group consisting of asthma, atherosclerosis, glomerulonephritis, pancreatitis, restenosis, rheumatoid arthritis, diabetic nephropathy, pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, and transplant rejection.
71. (new) The method of claim 68 where the allergic, inflammatory, or autoimmune disorder or disease is associated with lymphocyte and/or monocyte accumulation.
72. (new) A method of inhibiting leukocyte migration, comprising administering a therapeutically effective amount of a compound of claim 44 to a mammal in need of such treatment.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.